DexCom, Inc. (DXCM)

Market Cap	27.19B -18.5%
Revenue (ttm)	4.82B +16.2%
Net Income	930.40M +73.8%
EPS	2.34 +75.5%
Shares Out	385.87M
PE Ratio	30.05
Forward PE	26.40
Dividend	n/a
Ex-Dividend Date	n/a

Volume	91,081
Open	70.31
Previous Close	70.26
Day's Range	70.21 - 70.47
52-Week Range	54.11 - 89.98
Beta	1.40
Analysts	Strong Buy
Price Target	81.64 (+15.85%)
Earnings Date	Apr 30, 2026

About DXCM

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin;...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 14, 2005
• Employees: 11,100
• Stock Exchange: NASDAQ
• Ticker Symbol: DXCM
• Website: https://www.dexcom.com

Financial Performance

In 2025, DexCom's revenue was $4.66 billion, an increase of 15.60% compared to the previous year's $4.03 billion. Earnings were $836.30 million, an increase of 45.14%.

Analyst Summary

According to 28 analysts, the average rating for DXCM stock is "Strong Buy." The 12-month stock price target is $81.64, which is an increase of 15.85% from the latest price.

Price Target

$81.64

(15.85% upside)

Analyst Consensus: Strong Buy